<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00661544</url>
  </required_header>
  <id_info>
    <org_study_id>2003-0603</org_study_id>
    <nct_id>NCT00661544</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients</brief_title>
  <official_title>Phase I/II Study of the Combination of Arsenic Trioxide With Ascorbic Acid and High-Dose Melphalan for Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CTI BioPharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To evaluate the toxicity and safety of a combination of arsenic trioxide with ascorbic&#xD;
           acid and high-dose Melphalan in patients with multiple myeloma&#xD;
&#xD;
        2. To evaluate the efficacy of a combination of arsenic trioxide with ascorbic acid and&#xD;
           high-dose Melphalan in patients with multiple myeloma&#xD;
&#xD;
        3. To determine the effects of arsenic trioxide on melphalan pharmacokinetics&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment:&#xD;
&#xD;
      High-dose melphalan followed by a transplant of autologous stem cells is thought to be one of&#xD;
      the most effective ways to treat multiple myeloma. However, the number one cause of treatment&#xD;
      failure in these patients is the disease coming back.&#xD;
&#xD;
      High-dose melphalan has been used in multiple myeloma for more than two decades and is&#xD;
      considered the standard of care for this disease. Recent research in the laboratory and&#xD;
      clinical trials has shown that Arsenic trioxide is an effective treatment against multiple&#xD;
      myeloma. It leads to tumor cell death in myeloma cell lines and in myeloma patients. Arsenic&#xD;
      trioxide can also make melphalan a more effective antimyeloma agent. This research has also&#xD;
      shown that vitamin C enhances the anti-myeloma activity of arsenic trioxide by making it more&#xD;
      toxic to myeloma cells. The purpose of this study is to learn if a combination of arsenic&#xD;
      trioxide, vitamin C, and melphalan will be safe, well-tolerated and effective in myeloma&#xD;
      patients.&#xD;
&#xD;
      Before treatment begins, you will have several tests performed to study the status of the&#xD;
      disease before you begin taking the study medication. You will have a bone marrow aspirate&#xD;
      and biopsies. An aspirate is the drawing of liquid marrow with a syringe, while a biopsy is&#xD;
      the removal of a small core of bone with a hollow needle. Aspirate can be done from the hip&#xD;
      bone or chest, while biopsy is always from the hip bone. You will have cytogenic tests, to&#xD;
      see if there are any genetic abnormalities in your DNA. You will have a bone survey done,&#xD;
      where the doctor will look at X-rays of your bones for any myeloma-related bone changes.&#xD;
&#xD;
      You will have routine and specialized blood tests done (about 2 tablespoons), to measure&#xD;
      blood counts, platelets, blood clotting, kidney function, electrolyte counts, and levels of&#xD;
      disease in your blood. You will also have a urine test to measure level of myeloma in your&#xD;
      urine. You will have a pulmonary function test, to check if your lungs is strong enough to&#xD;
      withstand high-dose chemotherapy. You will have an initial electrocardiogram (EKG) and also a&#xD;
      MUGA scan that will measure how strong your heart functions are.&#xD;
&#xD;
      Women who are able to have children must have a negative blood pregnancy test before&#xD;
      participating in this study.&#xD;
&#xD;
      If you agree and are eligible, you will be assigned to receive one of 3 arms. In the first&#xD;
      arm only melphalan and vitamin C, but no Arsenic trioxide will be given. In the second and&#xD;
      third arms, doses of arsenic trioxide together with Vitamin C and melphalan will be given.&#xD;
      Not all patients in this study will get the same dose of arsenic. Your dose assignment will&#xD;
      depend on the experience of other patients with this combination. The first 3 patients on&#xD;
      this study will get the lowest dose of arsenic trioxide.&#xD;
&#xD;
      Arsenic trioxide will be given through a needle in the vein over a period of 2 hours, once a&#xD;
      day for 7 days. At the same time, vitamin C will be given once a day through the vein for 7&#xD;
      days. On the last 2 days of arsenic trioxide treatment, melphalan will be given through the&#xD;
      vein over one hour after the arsenic. You will have your stem cells reinfused 2 days after&#xD;
      the last dose of melphalan.&#xD;
&#xD;
      Some patients agreeing to the optional procedure will receive one of the doses of melphalan&#xD;
      before starting the arsenic.&#xD;
&#xD;
      You will receive standard inpatient and outpatient transplant care and testing. This involves&#xD;
      blood and bone marrow tests, heart tests, lung tests and x-rays before the study drug&#xD;
      treatment and the transplant. To collect a bone marrow sample, an area of the hip or chest&#xD;
      bone is numbed with anesthetic and a small amount of bone marrow is withdrawn through a large&#xD;
      needle. Blood tests (about two tablespoons) will be drawn at least once a week for the first&#xD;
      month after the transplant, and then once every month for the next 3 months.&#xD;
&#xD;
      Bone marrow biopsies and tests to check the level of myeloma protein in the urine and the&#xD;
      blood are also performed at 3, 6 and 12 months after the transplant.&#xD;
&#xD;
      You will be taken off study one year after transplant, if your disease does not come back.&#xD;
      Patients off study will still return for their routine post-transplant follow up visits as&#xD;
      decided by their transplant physician. If your disease comes back or intolerable side effects&#xD;
      occur, you will be taken off study.&#xD;
&#xD;
      This is an investigational study. Both arsenic trioxide and melphalan are commercially&#xD;
      available and have been approved for use in patients with myeloma, though their use together&#xD;
      with vitamin C is investigational. About 32 patients are expected to participate in this&#xD;
      study. All will be enrolled at UTMDACC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Bone marrow aspirate and biopsy performed to assess complete response and overall response rate.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Arsenic Trioxide + Vitamin C + Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arsenic Trioxide + Ascorbic Acid + Melphalan as a preparative regimen for autologous stem cell transplantation (delivered on Day 0)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arsenic Trioxide</intervention_name>
    <description>Dose Level 1: None; Dose Level 2: 0.15 mg/kg days Intravenous (IV) Days -9 to -3; Dose Level 3: 0.25 mg/kg days IV Days -9 to -3.</description>
    <arm_group_label>Arsenic Trioxide + Vitamin C + Melphalan</arm_group_label>
    <other_name>Trisenox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Dose Levels 1, 2, &amp; 3: 100 mg/m2 IV Days -4, -3.</description>
    <arm_group_label>Arsenic Trioxide + Vitamin C + Melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Dose Levels 1, 2, &amp; 3: 1000 mg IV Days -9 to -3.</description>
    <arm_group_label>Arsenic Trioxide + Vitamin C + Melphalan</arm_group_label>
    <other_name>Vitamin C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with Multiple Myeloma in any of the following disease categories: a) Primary&#xD;
             Refractory Disease b) Consolidation of a partial remission (defined as a decrease but&#xD;
             continued presence of monoclonal protein on serum and urine immunofixation&#xD;
             electrophoresis, and/or the presence of plasmacytosis on bone marrow aspirate and&#xD;
             biopsy) c) All patients relapsing after prior therapy .&#xD;
&#xD;
          2. Age up to 70 years.&#xD;
&#xD;
          3. Zubrod Performance Status (PS) of &lt;2.&#xD;
&#xD;
          4. Left ventricular ejection fraction &gt;40%. No uncontrolled arrhythmias or symptomatic&#xD;
             cardiac disease.&#xD;
&#xD;
          5. Forced vital capacity (FVC); Forced expiratory volume in 1 second (FEV1), forced vital&#xD;
             capacity (FVC) and Carbon Monoxide Diffusing Capacity (DL CO) &gt;40%. No symptomatic&#xD;
             pulmonary disease.&#xD;
&#xD;
          6. Serum bilirubin &lt;2 times upper limit of normal, SGPT &lt;4 times upper limit of normal.&#xD;
             No evidence of chronic active hepatitis or cirrhosis. No effusion or ascites &gt;1L prior&#xD;
             to drainage.&#xD;
&#xD;
          7. HIV-negative.&#xD;
&#xD;
          8. Patient is not pregnant.&#xD;
&#xD;
          9. Patient or guardian able to sign informed consent.&#xD;
&#xD;
         10. Corrected QT interval less than 500 msec.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Corrected QT interval greater than 500 msec&#xD;
&#xD;
          2. Patients in complete remission (defined as the absence of monoclonal protein on serum&#xD;
             and urine immunofixation electrophoresis, and the absence of plasmacytosis in bone&#xD;
             marrow aspirate and biopsy).&#xD;
&#xD;
          3. Patients with non-secretory myeloma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muzaffar H. Qazilbash, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas (UT) MD Anderson Cancer Center official website</description>
  </link>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>April 15, 2008</study_first_submitted>
  <study_first_submitted_qc>April 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2008</study_first_posted>
  <results_first_submitted>March 13, 2009</results_first_submitted>
  <results_first_submitted_qc>May 21, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 14, 2009</results_first_posted>
  <last_update_submitted>February 26, 2013</last_update_submitted>
  <last_update_submitted_qc>February 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Ascorbic Acid</keyword>
  <keyword>Vitamin C</keyword>
  <keyword>Arsenic Trioxide</keyword>
  <keyword>Trisenox</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Autologous Stem Cell Transplant</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 03/31/2004 through 08/02/2005. All pariticipants recruited at U.T. M.D. Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arsenic Trioxide + Vitamin C + Melphalan</title>
          <description>Arsenic Trioxide + Ascorbic Acid + Melphalan as a preparative regimen for autologous stem cell transplantation (delivered on Day 0)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arsenic Trioxide + Vitamin C + Melphalan</title>
          <description>Arsenic Trioxide + Ascorbic Acid + Melphalan as a preparative regimen for autologous stem cell transplantation (delivered on Day 0)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" lower_limit="35" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Bone marrow aspirate and biopsy performed to assess complete response and overall response rate.</description>
        <time_frame>3, 6 and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arsenic Trioxide + Vitamin C + Melphalan</title>
            <description>Arsenic Trioxide + Ascorbic Acid + Melphalan as a preparative regimen for autologous stem cell transplantation (delivered on Day 0)</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Bone marrow aspirate and biopsy performed to assess complete response and overall response rate.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Response (Complete + Partial Response)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years and 1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arsenic Trioxide + Vitamin C + Melphalan</title>
          <description>Arsenic Trioxide + Ascorbic Acid + Melphalan as a preparative regimen for autologous stem cell transplantation (delivered on Day 0)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Muzaffar H. Qazilbash, MD / Associate Professor</name_or_title>
      <organization>U.T. M.D. Anderson Cancer Center</organization>
      <phone>713-745-3458</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

